Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GATT "substantial investment" would require ANDA acceptance prior to June 8, 1995 under Hatch amendment.

Executive Summary

GATT "SUBSTANTIAL INVESTMENT" REQUIRES ANDA ACCEPTANCE PRIOR TO JUNE 8, 1995 under a replacing amendment by Sens. Hatch (R-Utah) and Specter (R-Penn.) during Judiciary Committee mark-up May 2 of legislation on marketing of generic drugs during the extended patent period under the General Agreement on Tariffs & Trade. The committee voted 10-7 to accept the Hatch/Specter amendment to replace the original bill offered by Sens. Pryor (D-Ark.), Brown (R-Colo.) and Chafee (R-R.I.).

Latest Headlines
See All
UsernamePublicRestriction

Register

PS028090

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel